NA
TRIB

Navellier & Associates’s Trinity Biotech TRIB Stock Holding History

Navellier & Associates’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,097
Closed -$33K – 350
2021
Q3 		$33K Sell
3,097
-17,025
-85% -$200K 0.01% 308
2021
Q2 		$296K Buy
20,122
+3,773
+23% +$62.8K 0.04% 250
2021
Q1 		$307K Buy
16,349
+3,353
+26% +$80.6K 0.06% 231
2020
Q4 		$248K Buy
+12,996
New +$215K 0.04% 245

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Navellier & Associates's TRIB Position: Q4 2021 in Review

Navellier & Associates sold out of Trinity Biotech (TRIB) in Q4 2021, closing a stake of 3,097 shares — an estimated $33K sold.

Navellier & Associates first reported a position in TRIB in Q4 2020 and held it in 4 quarters. The position peaked at $307K in Q1 2021. 21 funds tracked by Wall St. Rank hold TRIB as of Q4 2021.

  • Navellier & Associates reported no remaining Trinity Biotech position as of Q4 2021 after selling out during the quarter.
  • Navellier & Associates sold 3,097 Trinity Biotech shares in Q4 2021, an estimated $33K.
  • Navellier & Associates first reported a position in Trinity Biotech in Q4 2020 and held it in 4 quarters.
  • Navellier & Associates's Trinity Biotech position peaked at $307K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2021.

Based on Navellier & Associates's 13F filing for Q4 2021, filed 14 Feb 2022.